main results and the role of chance: The women under 36 years of age were three times more likely to get pregnant after PGD treatment, P ¼ 0.003 and odds ratio 3.1 [95% confidence interval (CI) 1.5-6.5]. The 1-cell biopsy cycles were twice as likely to result in a pregnancy in comparison with cycles were 2 cells were removed from the embryo, P ¼ 0.0013 and odds ratio 2.55 (95% CI 1.44-4.52). No other factors were found to be significant for the outcome. 
Introduction
Since the first implementation of preimplantation genetic diagnosis (PGD) at the beginning of 1990 (Handyside et al., 1990) , the diagnostic procedure has been constantly improved and refined, and PGD is currently an established alternative to prenatal diagnosis for couples with a high risk of having offspring affected by a severe genetic disorder.
The advantage of PGD is that the embryo may be tested before a pregnancy is established, and thereby a possible termination of the pregnancy can be avoided. The disadvantage of PGD is that the couple needs to go through an IVF treatment, which in itself can be a physically and psychologically demanding process (Olivius et al., 2004) . In addition, the economic aspects of the treatment may be considered. The success rate of PGD is often lower than that of routine assisted reproductive technologies. This may be an effect of the biopsy of the embryos, as well as the loss of genetically affected embryos that results in fewer embryos to transfer. However, for certain indications, such as inherited chromosome disorders where the carriers often have a history of recurrent pregnancy losses, the pregnancy outcome has actually been shown to be improved with PGD (Fischer et al., 2009) . Most PGD patients do not have fertility problems, and before a PGD treatment is started it is important that a thorough evaluation of each couple is made by specialists in both genetics and fertility treatment. Each couple should be given adequate information, including the expected success rate, in order to be able to make a well-informed decision regarding different reproductive options. The yearly increase in the number of treatments as well as new indications, suggests that PGD is the preferred alternative for an increasing number of couples (Harper et al., 2010) .
The Stockholm PGD centre is the larger of two PGD centres in Sweden, and is a full member of the ESHRE PGD Consortium. We have made a retrospective analysis of data from the first 14 years of PGD activity at the Stockholm PGD centre, including pregnancy follow up, and reported the findings. The aim of the study was to identify parameters of importance for a successful PGD treatment in order to improve the results, better counsel patients with genetic conditions in their choice of different reproductive alternatives and to better customize the treatment for each couple.
Materials and Methods

Patients
All the couples were referred for evaluation to both a geneticist and a fertility specialist. They were informed about the treatment procedure and the expected outcome. An assessment by the geneticist whether a genetic analysis could be established for the specific couple was made and an evaluation of the woman's ovarian reserve, medical status and the probability of success with the PGD treatment was carried out by the fertility specialist.
The data analyses were made in retrospect including all the PGD cycles performed at our centre from 1996 to 2009. During this period, 569 treatments for 256 couples were performed, thawing cycles excluded. The number of cycles per couple varied between one and five. The delivery rate is given per stimulation, embryo transfer and per couple. The indications for PGD were divided into three main groups which were further subdivided into seven different subgroups. The main groups were (i) chromosome abnormalities (Table I) , (ii) autosomal single gene disorders (Table II) and (iii) X-linked disorders (Table III) . Chromosome abnormalities (Table I) were subdivided into reciprocal translocations, Robertsonian translocations and other chromosome rearrangements. Autosomal single gene disorders (Table II) were subdivided according to inheritance into autosomal dominant and autosomal recessive disorders. The most common diagnoses of these were; Myotonic dystrophy, Huntington disease and Von Hippel Lindau disease. The X-linked disorders (Table III) were subdivided into cases where sexing was performed and cases where mutation detection was used. The most frequent X-linked diagnoses were Fragile X, Duchenne muscular dystrophy (DMD) and haemophilia A. The distribution was 54% chromosomal abnormalities, 32% monogenic disorders and 14% X-linked disorders. Interphase FISH was mainly used for the detection of chromosome rearrangements and sexing. FISH was also used in two cases of DMD for the detection of DMD deletions (Malmgren et al., 2006) . PCR analysis, mainly with multiplex linkage markers, was applied for monogenic disorders with specific mutations and for X-linked disorders where mutation detection was performed. When there were at least three follicles ≥18 mm, Choriongonadotrophin or Choriongonadotrophin alfa was injected subcutaneously to induce maturation and luteinization in the follicles, and 37 h later oocyte retrieval (OR) was performed. Two days after OR, vaginal micronized progesterone (1200 mg daily) was added and continued until the pregnancy test 16 days later. IVF was performed in cases where FISH analyses were used. ICSI was performed for all indications where PCR analyses were used and in cases of male factor infertility irrespective of the genetic method. The oocytes were fertilized and the zygotes were transferred into sequential culture media innovative sequential media (ISM) 1 Day 0 -2 and ISM 2 Day 3 -6 (MediCult, Jyllinge, Denmark) and individually cultured in microdroplets under oil. Cumulus cells were removed by hyaluronidase treatment (Vitrolife, Gothenburg, Sweden) before ICSI.
Stimulation and fertilization technique
Biopsy procedure
On Day 3 after OR, a cleavage stage biopsy (1 or 2 cells) was performed if the embryos contained 6 cells or more. Using acidified Tyrode's solution (pH 2.5), a hole in the zona was drilled, followed by the removal of 1 or 2 cells . Initially, 2-cell biopsy policy was applied for almost all indications, but after 2003, 1-cell biopsy policy was applied when possible with respect to the reliability of the diagnostic test. One-cell biopsy was mainly applied when FISH analysis with an optimal probe set up was used. Since 2009, 1-cell biopsy policy has also been applied for monogenic disorders, with linkage analysis using PCR analysis of multiple markers. Therefore, for each cycle, the policy was either 1-cell biopsy or 2-cell biopsy, depending on the reliability of the specific diagnostic test. However, for this study, the allocation to the 1-cell or the 2-cell group was dependent on whether the actual transferred embryo had been subjected to 1-or 2-cell removal. (The biopsy plan cannot always be carried out for each embryo in the cycle).
Genetic diagnosis
From the start in 1996 until 1999, PGD was performed for chromosome rearrangements only. In 2000, PGD for monogenic disorders was introduced, and today constitutes more than half of the PGD cycles. Preimplantation genetic screening and PGD for social sexing are not allowed in Sweden.
FISH-based PGD
Interphase FISH analysis was used to distinguish balanced and unbalanced pre-embryos for carriers of structural chromosome aberrations. For Robertsonian translocations, a set of two or three DNA probes were used, located on the chromosomes involved. For reciprocal translocations, a set of three or four DNA probes were used, flanking the breakpoints on the chromosomes involved. FISH analysis was also used for sexdetermination for X-linked disorders, in order to be able to do a selective transfer of female embryos. In two cases of PGD for DMD, FISH was used for the detection of DMD deletions (Malmgren et al., 2006) . The interphase FISH analyses were performed according to standard procedures and as previously described with the modification that hybridization was performed at 378C over night.
PCR-based PGD
The strategy to distinguish affected and unaffected pre-embryos for carriers of monogenic disorders was in most cases linkage analysis. In each family, a set of at least two polymorphic markers, intragenic or closely flanking the disease gene was identified. In most cases three to six markers were included in the analysis. For X-linked diseases, a marker for sex determination (amelogenin gene) was included. A multiplex PCR analysis was then established and the accuracy evaluated on single cells. In cases with Myotonic Dystrophy type 1 or Huntington disease, the detection of the CGT/CAG repeat was used in the diagnostic setting.
Embryo transfer procedure
The results of the analyses were available on Day 4 or 5 after OR, and if possible, one or two unaffected embryos were transferred. If additional unaffected embryos were surplus after embryo transfer, they were cultured until Day 5 or 6 after OR and then cryopreserved if they had formed blastocysts.
Statistics
The characteristics of the cohort were defined using absolute and relative frequencies for categorical variables, and means and medians with measures of spread for continuous variables. Comparisons of continuous variables were made using Student's t-test and the Mann -Whitney test.
Comparisons of categorical data were made using x 2 and Fishers exact test when appropriate. Lineal regression analyses were used to identify the significant factors for the outcome. Multivariate models were constructed to determine the potential confounding factors. The following predictors were included in the models: indication, carrier, woman's age at stimulation start, parity, number of oocytes received at OR, type of fertilization, number of oocytes fertilized and number of cells biopsied and analyzed. The receiver operating characteristic curve was used to analyse the predictive accuracy of the different parameters. A P-value of ≤ 0.05 was considered significant.
Results
Patient and treatment characteristics
The characteristics are given as numbers and percentage. The overall mean age of the women at stimulation start was 33.7 years (22 -43).
Ten percent of all started cycles were cancelled before OR. Embryo biopsy was possible in 83.7%, and embryo transfer was possible in 63.3% of all started cycles. Twenty-four percents of the cycles with embryo transfer resulted in a positive pregnancy test, and 22% resulted in a clinical pregnancy. The overall pregnancy loss rate was 16.3%. The overall delivery rate was 11.2% per started cycle and 17.8% per embryo transfer. Detailed information on patient and treatment characteristics for each group is presented in Tables I -III. The majority of pregnancies were achieved during the first two treatments. When a logistic regression analysis of the overall data was made, there were two important factors that appeared to be statistically significant for the pregnancy outcome. Firstly, the age of the woman at stimulation start; the women under 36 years of age were three times more likely to get pregnant P ¼ 0.003 and odds ratio 3.1 [95% confidence interval (CI) 1.5-6.5]. Secondly, the number of biopsied cells from each embryo had an impact on the pregnancy outcome; the cycles where 1 cell was removed were twice as likely to result in a pregnancy in comparison with the cycles where 2 cells were removed, P ¼ 0.0013 and an odds ratio 2.55 (95% CI 1.44-4.52). The delivery rate per embryo transfer was 29.5% after biopsy with 1-cell removal and 14% after 2-cell removal. Detailed information on these groups is presented in Table IV .
The allocation to each group-1-cell or 2-cell removal-refers to the transferred embryo and not to the specific PGD cycle. There were 16 cycles of mixed transfers (one embryo with one cell biopsy and one embryo with 2-cell biopsy). They were allocated to the 2-cell biopsy group. When comparing 1-and 2-cell biopsy in different subgroups, we found the same result, e.g. in the translocation group (reciprocal and Robertsonian), the delivery rate per embryo transfer was 28.6% after 1-cell removal and 14.7% after 2-cell removal. The number of 1-cell biopsy cycles was 81 and 2-cell biopsy cycles 159. There was no significant difference in the age of the woman (32.9 and 33.2, respectively). The embryo transfer rate was 69% in both groups. Detailed information is presented in the tables. An explanation to the higher success rate in the 1-cell biopsy group could be that these cycles were performed mainly during the later years, when the laboratory was more sophisticated. However, a comparison over time regarding 1-and 2-cell removal shows that there were only four cycles with 1-cell removal from 1996 to 2003. During the years from 2004 to 2009, the results were the same, as in the whole cohort comparing 1-and 2-cell biopsy. Looking at the 2-cell biopsy group in the early and the late phases, there were 113 cycles in the early phase and 245 cycles in the late phase, the mean age was 33 and 34 years, respectively, and the delivery rate per embryo transfer was 14% in both groups. This implies that the general performance of the laboratory has not changed over time.
Other characteristics such as parity, carrier status, number of oocytes at OR and type of fertilization did not influence the pregnancy outcome significantly in our cohort.
The thawing cycles were not included in the statistical analyses and the pregnancy rate per couple reflects repeated fresh cycles only.
Discussion
From the start in 1996 until 2009, 569 PGD cycles were performed at the Stockholm PGD centre. During this period, there was a rising request for PGD and the number of indications for which PGD was performed increased every year (Fig. 1) . Retrospect analyses of these results and the logistic procedure show that there were two significant factors for a successful treatment; the woman's age and the number of biopsied cells per embryo. The women under 36 years of age were three times more likely to achieve a pregnancy. This confirms the results presented by other groups (Feyereisen et al., 2007; Verpoest et al., 2009 ). In addition, in our cohort, the number of biopsied cells per embryo had a huge impact on the delivery rate. The delivery rate was 29.5% after 1-cell removal, compared with only 14% after 2 cells had been removed. The same figures were confirmed in the chromosomal abnormality group (Robertsonian and reciprocal translocation). These figures were not dependent on the indications for PGD. Similar results were reported by De Vos et al. (2009) . Other groups have previously raised the question whether the removal of 2 cells might have a negative effect on the pregnancy outcome (Pickering et al., 2003; Cohen et al., 2007) . Some have argued that the 2-cell biopsy group may contain more rapidly developing and better quality embryos and therefore have a better implantation potential (Van de Velde et al., 2000) . This theory was not supported by our results. There has also been a justified fear that the diagnostic efficiency (number of successfully diagnosed embryos) may be affected by analysing 1 cell only (Fiorentino et al., 2006; Goossens et al., 2008) . In our material, there were no differences in the success rate of the genetic analysis, 93 versus 95% for the 1-cell and the 2-cell groups, respectively, or in the embryo transfer rate, which was 75 versus 76%. In addition, to the best of our knowledge, there is no case of misdiagnosis in our material. Therefore, the advantages in delivery rate after 1-cell biopsy seem to overweigh the possible disadvantages. However, 1-cell biopsy sets a greater demand on the design and accuracy of the genetic test for each patient, as the possibility of using the two biopsied cells as controls of one another is lost. To compensate for this shortcoming, four DNA-probes for interphase FISH analysis of reciprocal translocations may be used, or three DNA-probes with optimal localization, i.e. chromosome segregation likely to give rise to viable offspring should give unbalanced FISH-signal patterns with an internal 'check'. This means that failure of one signal or co-localization would still give an abnormal signal pattern (Scriven et al., 1998) . The strategy to use linkage analysis with multiple markers for the PCR-based analysis, and if possible in combination with mutation detection, also allows a reliable test on 1-cell. There are, however, situations where the diagnostic test is sub-optimal and the 2-cell biopsy strategy may therefore still be considered the best choice for certain couples. It is important to make a separate evaluation of each case and to ensure that the couple is well informed about their individual, calculated risk of possible misdiagnosis.
In contrast to previous publications (Grace et al., 2006; Verpoest et al., 2009 ), we did not find a significant correlation between the number of collected oocytes and the delivery rate in our logistic model. Nor did parity, carrier status or indication for PGD affect the outcome. There was a surprisingly low delivery rate in the autosomal recessive group, even if they had embryo transfer to a greater extent than the autosomal dominant group. In theory, the autosomal recessive group is expected to have 75% unaffected embryos, and hence, a better chance to have a genetically suitable embryo for transfer than other indications. The results may be explained by the fact that in the majority of cycles 2 cells were biopsied, and also by the fact that the mean age of the woman at stimulation start was higher in this group than in the other groups; 35.5 years (27 -40) compared with the autosomal dominant group, where the mean age of the woman was 33.2 years (24-41) and the recombinant translocation group, where it was 33.6 years (22 -42). This in turn could be a consequence of the fact that most couples are not aware that they are carriers of an autosomal recessive disorder until they give birth to an affected child. This often means that they lose valuable time during their most fertile period. As previously reported by Fridströ m et al. (2001) , when comparing Robertsonian versus with reciprocal translocations, we find that the Robertsonian translocation group is more likely to have an embryo transfer. However, if a woman from the reciprocal translocation group has an embryo transfer, the chance of establishing a pregnancy is even slightly higher than for a woman from the Robertsonian group. In the Robertsonian group, the couple was more likely to conceive if it was the woman who was the carrier of the translocation, which is in contrast to the Retrospective analysis of 569 PGD cycles reciprocal translocation group where the chance of conception was higher if the man was the carrier of the translocation.
The cancellation rate of 10% in our cohort is lower than reported by others (Feyereisen et al., 2007; Grifo et al., 2007) , which may negatively affect the results regarding pregnancy outcome. With a more strict selection regarding the women's age at stimulation start and number of developing follicles during stimulation and at OR, this selected group of patients will have a higher success rates with the PGD treatment.
Even though the chance of achieving a pregnancy after PGD might be lower for certain patients than with natural conception, there will still be those that prefer PGD because of ethical or psychological reasons. The increasing demand for PGD makes it important that the procedure and results are reviewed and evaluated at regular intervals in order to optimize the treatment for future patients.
This is a retrospective analysis with the limitation that no randomization procedure has been performed and the different groups are not homogenous. In order to minimize this problem, a multiple stepwise logistic regression analysis was carried out, where the different predictors in the analysis were compared with one another. There were no missing posts in the different predictors which makes the analysis more reliable. We therefore think that the results may contribute to the ongoing discussion regarding the optimization of PGD treatments.
In conclusion this retrospective cohort analysis of 569 PGD treatments for 256 couples revealed two factors that significantly affected the pregnancy outcome; the woman's age at stimulation start and the number of biopsied cells. Furthermore, the use of 1-cell biopsy did not have a negative impact on the accuracy of the test in our material. Accordingly, we have now introduced an age limit of 40 years at the start of stimulation and the biopsy policy at our centre has been shifted towards 1-cell biopsy as the primary choice. Additional randomized studies comparing 1-cell biopsy with 2-cell biopsy are warranted in order to support or confirm these results.
